𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Metformin inhibits dipeptidyl peptidase IV activity in type 2 diabetes

✍ Scribed by J. R. Lindsay; N. Duffy; A. M. McKillop; J. Ardill; F. P. M. O’Harte; P. R. Flatt; P. M. Bell

Publisher
Springer-Verlag
Year
2002
Tongue
English
Weight
231 KB
Volume
171
Category
Article
ISSN
1863-4362

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Type 2 diabetes—Therapy with dipeptidyl
Type 2 diabetes—Therapy with dipeptidyl peptidase IV inhibitors
✍ Hans-Ulrich Demuth; Christopher H.S. McIntosh; Raymond A. Pederson 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 803 KB

The sole application of an inhibitor of the dipeptidyl peptidase DP IV (also DP 4, CD26, DPP-IV or DPP-4) to a mammal subsequently leading to improved glucose tolerance marks a major breakthrough in metabolic research bearing the potential of a new revolutionary diabetes therapy. This was demonstrat

ChemInform Abstract: The Asymmetric Synt
ChemInform Abstract: The Asymmetric Synthesis of Sitagliptin, a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes.
✍ Feng Liu; Wansheng Yu; Wenhua Ou; Xiaoke Wang; Libo Ruan; Yiming Li; Xijiang Pen 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 23 KB 👁 1 views

## Abstract Key step in the improved synthetic pathway to sitagliptin (VII), a new DPP‐IV inhibitor for the treatment of type 2 diabetes mellitus, is an asymmetric Michael addition to give intermediate (IV).